Celgene Corp (CELG.O)
123.12USD
20 May 2013
$-1.79 (-1.43%)
$124.91
$124.60
$125.17
$122.55
2,243,366
3,281,749
$131.82
$58.53
CELG.O
About
Overall
| Beta: | 0.67 |
| Market Cap (Mil.): | $51,356.12 |
| Shares Outstanding (Mil.): | 417.12 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CELG.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 37.36 | 54.65 | 35.85 |
| EPS (TTM): | 3.30 | -- | -- |
| ROI: | 15.04 | 0.83 | 18.76 |
| ROE: | 24.75 | 1.79 | 19.57 |
Celgene raises 2013 profit forecast, shares rise
- Biotechnology firm Celgene Corp reported a first-quarter profit that edged past analysts' estimates on strong demand for its cancer drugs, Revlimid and Abraxane, and it raised its full-year earnings forecast.
UPDATE 1-Celgene raises 2013 profit forecast, shares rise
April 25 - Biotechnology firm Celgene Corp reported a first-quarter profit that edged past analysts' estimates on strong demand for its cancer drugs, Revlimid and Abraxane, and it raised its full-year earnings forecast.
Celgene profit beats estimates as demand for cancer drugs rise
April 25 - Biotechnology firm Celgene Corp reported a first-quarter profit that edged past analysts' estimates on strong demand for its cancer drugs, Revlimid and Abraxane, and it raised its 2013 earnings forecast.
BRIEF-Celgene down in premarket after psoriasis drug trial results
NEW YORK, March 4 - Celgene Corp : * Down 2.2 percent to $103.26 in premarket after psoriasis drug trial results
Celgene drug shown to be effective, safe in psoriasis trial
- Celgene Corp's experimental drug apremilast proved to be more effective than a dummy pill for psoriasis patients in a late-stage study, clearing the way for the company to file for U.S. regulatory approval in the second half of 2013.
Celgene drug shown to be effective, safe in psoriasis trial
March 2 - Celgene Corp's experimental drug apremilast proved to be more effective than a dummy pill for psoriasis patients in a late-stage study, clearing the way for the company to file for U.S. regulatory approval in the second half of 2013.
Celgene wins Chinese regulatory OK for Revlimid
- Celgene Corp on Monday said its drug Revlimid won full regulatory approval in China for patients with relapsed or refractory multiple myeloma, a type of cancer that starts in the plasma cells in the bone marrow.
Celgene wins Chinese regulatory OK for Revlimid
Feb 11 - Celgene Corp on Monday said its drug Revlimid won full regulatory approval in China for patients with relapsed or refractory multiple myeloma, a type of cancer that starts in the plasma cells in the bone marrow.
FDA approves Celgene drug for multiple myeloma
- U.S. regulators have approved a new drug from Celgene Corp for patients with multiple myeloma whose disease has worsened after being treated with other cancer drugs.
UPDATE 1-FDA approves Celgene drug for multiple myeloma
Feb 8 - U.S. regulators have approved a new drug from Celgene Corp for patients with multiple myeloma whose disease has worsened after being treated with other cancer drugs.
Competitors
| Price | Change | |
|---|---|---|
| Amgen, Inc. (AMGN.OQ) | $102.18 | -3.45 |
| AstraZeneca plc (AZN.L) | 3,367.50p | -23.00 |
| Biogen Idec Inc. (BIIB.OQ) | $225.18 | -1.67 |
| Bristol Myers Squibb Co. (BMY.N) | $43.76 | +0.46 |
| Bristol Myers Squibb Co. (BMY_p.N) | $567.60 | 0.00 |
| Eisai Co., Ltd (4523.T) | ¥4,455 | -5.00 |
| Johnson & Johnson (JNJ.N) | $88.01 | -0.08 |
| Merck & Co., Inc. (MRK.N) | $45.21 | -0.78 |
| Novartis AG (NOVN.VX) | CHF71.60 | -0.15 |
| Pfizer Inc. (PFE.N) | $28.70 | -0.26 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
